Navy Announces Expansion of Urinalysis Testing Program

Story Number: NNS190603-07Release Date: 6/3/2019 1:44:00 PM
A  A  A   Email this story to a friend   Print this story
From Chief of Naval Personnel Public Affairs

WASHINGTON (NNS) -- Navy announced that the Department of Defense has expanded its ability to conduct random drug testing for manufactured opiate drugs June 3, in NAVADMIN 125/19.  

Effective immediately, Navy Drug Screening Laboratories will add Fentanyl and Norfentanyl to the standard drug testing panel for urinalysis samples.  

Navy policy remains clear with regard to substance abuse:  Zero Tolerance.  Sailors determined to be abusing drugs will be subject to punitive action under the Uniform Code of Military Justice (UCMJ), Article 112a.  

Sailors who test positive for drugs will be processed for administrative separation and could receive an “Other Than Honorable” discharge, which can affect their veteran benefits and employment opportunities.  In addition, the Navy reports unlawful drug users to the Federal Bureau of Investigation for inclusion in the National Instant Criminal Background Check System (NICS), which impacts the ability to purchase firearms or ammunition. 

It is the responsibility of every Sailor to ensure that he or she avoids intentional or accidental exposure to federally-prohibited substances.  

For Navy drug testing policy questions and concerns, contact Mrs. LaNorfeia Parker, Director, Navy Drug Detection and Deterrence, OPNAV N17 at (901) 874-4249/DSN 882 or via e-mail at  

For more information about Navy Drug Detection and Deterrence or the Navy Drug Screening Program, visit and click 21st Century Sailor.

Get more information about the Navy from US Navy facebook or twitter.

For more news from Chief of Naval Personnel, visit

Navy Social Media
Sign up for email updates To sign up for updates or to access your subscriber preferences, please click on the envelope icon in the page header above or click Subscribe to Navy News Service.